文献速递核素与放射性配体治疗神经核医学肿瘤 PET/CT

177Lu-DOTATATE靶向放射性核素治疗控制伴孤立肾与MEN-1综合征的转移性胰岛素瘤

Metastatic Insulinoma Controlled by Targeted Radionuclide Therapy With 177Lu-DOTATATE in a Patient With Solitary Kidney and MEN-1 Syndrome.
PubMed 文献 · Clin Nucl Med · 2019-01-01

本文报告一例54岁男性多发性内分泌腺瘤病1型(MEN-1)患者,既往有甲状旁腺手术及左侧甲状腺叶切除史,因反复低血糖就诊。

要点

  • 伴孤立肾与MEN-1综合征的转移性胰岛素瘤可考虑177Lu-DOTATATE靶向治疗。
  • 每日低血糖发作在1年随访中减少至1次。

核心结论

  • 伴孤立肾与MEN-1综合征的转移性胰岛素瘤患者经177Lu-DOTATATE治疗后获得影像学与临床低血糖改善。

研究设计与样本

  • 单例病例报告:54岁男性MEN-1患者,既往甲状旁腺手术及左侧甲状腺叶切除5年,因反复低血糖转诊。

主要发现

  • 每日发作的低血糖在1年随访中减少至1次。

临床怎么用

  • 对MEN-1相关转移性胰岛素瘤且伴孤立肾者,177Lu-DOTATATE可作为控制肿瘤与低血糖的靶向放射性核素治疗选择。

局限性

  • 本文为单例病例报告,证据级别有限,结论需更大样本研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 54-year-old man with multiple endocrine neoplasia type 1 had previous history of parathyroid surgery and left thyroid lobectomy 5 years earlier, and was referred for recurrent hypoglycemic episodes. Ga-DOTATATE PET/CT had showed multiple lesions in the right lung, liver, and pancreas. Biopsy from pancreas revealed low-grade neuroendocrine neoplasia. After 2 fractions of Lu-DOTATATE therapy, the size of lesions and its activity reduced on the Ga-DOTATATE scan and the hypoglycemic episodes manifested every day have scaled down to 1 time over 1-year follow-up. Herein, we report a case of malignant insulinoma successfully treated with radiolabeled somatostatin receptor therapy using Lu-DOTATATE.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Novruzov F, Mehmetbeyli L, Aliyev JA, et al. Metastatic Insulinoma Controlled by Targeted Radionuclide Therapy With 177Lu-DOTATATE in a Patient With Solitary Kidney and MEN-1 Syndrome. Clin Nucl Med. 2019. PMID: 30789400. doi:10.1097/RLU.0000000000002500

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。